Making News on Heart.org

Raising the systolic blood pressure threshold from 140 to 150 mmHg as a new target for high blood pressure treatment in people 60 and older could increase stroke risk.

The increased stroke risk associated with systolic blood pressures of 140 mmHg and higher is more pronounced among Hispanics and blacks.

Embargoed until 3 p.m. CT / 4 p.m. ET Mon., Feb. 1, 2016

DALLAS, Feb. 1, 2016 — Raising the systolic blood pressure threshold from 140 to 150 mmHg, as a new target for high blood pressure treatment in older people who don’t have chronic kidney disease or diabetes, could put this population at greater stroke risk, according to new research in the American Heart Association’s journal Hypertension.

The increased stroke risk is even more pronounced among Hispanics and blacks, the research showed.

In 2014, panel members appointed to the Eighth Joint National Committee, known as the JNC 8, published a paper in the Journal of the American Medical Association recommending treatment of high blood pressure in people 60 years and older whose systolic pressure – the top number in a blood pressure reading – was 150. The paper, however, was not an official guideline.

“We started this analysis very soon after [the JAMA paper] came out … because we were concerned about the recommendation’s potential effect on stroke prevention,” said study author Ralph L. Sacco, M.D., professor and chair of neurology at the University of Miami Miller School of Medicine.

Sacco and colleagues from University of Miami and Columbia University studied 1,750 people ages 60 years and older, who were free of stroke, diabetes and chronic kidney disease.

Researchers measured participants’ systolic blood pressure at the study’s start and noted during an average 13 years if any of those patients had strokes. Among those studied, 63 percent were women, 48 percent were Hispanic, 25 percent white, and 25 percent black. Forty-three percent of participants had systolic readings of less than 140 mmHg; 20 percent were between 140 and 149 mmHg; and 37 percent had systolic pressures of 150 mmHg and higher.

They found:

Over the median 13 years of follow-up, 182 people developed stroke.

Having a systolic blood pressure of 140 to 149 mmHg elevated stroke risk as much as having systolic blood pressure greater than 150.

Those with 140 mmHg systolic blood pressure and higher at the start of the study were 70 percent more likely to suffer a stroke compared to adults with normal systolic pressure, which is less than 140 mmHg.

The increased stroke risk was most notable among Hispanics and non-Hispanic blacks.

“The findings suggest one should not liberalize or change the treatment threshold for blood pressure in people older than 60 without chronic kidney disease or diabetes. For stroke prevention, maintaining a blood pressure target of 140 mmHg is important,” Sacco said.

There are limitations to the study, according to Sacco. One is that it’s an observational, not a randomized study, which means the researchers observed what happened in the study population rather than randomly assigning people to treatment groups for comparison. A study strength is that it had strong minority representation. That’s important, Sacco said, because blacks and Hispanics have greater risks of stroke and more hypertension than whites.

“As a result, more aggressive treatment of blood pressure in those population groups is even more critical,” he said. “In general, our findings support adherence to the current American Heart Association guidelines that consistently recommend treatment for blood pressure above 140-90 mmHg in order to improve cardiovascular health and reduce stroke.”

For the latest blood pressure science, follow the Hypertension journal at @HyperAHA

###

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.